Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ecopipam - Emalex Biosciences

X
Drug Profile

Ecopipam - Emalex Biosciences

Alternative Names: EBS-101; Ecopipam HCl; PSYRX 101; SCH-39166

Latest Information Update: 23 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Schering-Plough
  • Developer Emalex Biosciences; Psyadon Pharmaceuticals; Schering-Plough
  • Class Alcohols; Antipsychotics; Behavioural disorder therapies; Benzazepines; Cardiovascular therapies; Chlorinated hydrocarbons; Drug withdrawal therapies; Heterocyclic compounds with 4 or more rings; Naphthalenes; Obesity therapies; Small molecules
  • Mechanism of Action Dopamine D1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lesch-Nyhan syndrome; Gilles de la Tourette's syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gilles de la Tourette's syndrome; Lesch-Nyhan syndrome
  • Phase II Speech disorders
  • Phase I/II Restless legs syndrome
  • Phase I Cardiovascular disorders
  • No development reported Gambling
  • Discontinued Cocaine-related disorders; Obesity; Schizophrenia

Most Recent Events

  • 18 Jan 2024 Emalex Biosciences initiates a phase I drug-drug interaction trial (In Volunteers) in Canada (NCT06194864)
  • 08 Jan 2024 Emalex Biosciences plans a phase I drug drug interaction trial (In Volunteers) in Canada, in January 2024 (NCT06194864)
  • 05 Oct 2023 Efficacy and adverse events data from a phase II trial in Gilles de la Tourette's syndrome released by Emalex Biosciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top